{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:43:35Z","timestamp":1792539815053,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,26]],"date-time":"2015-12-26T00:00:00Z","timestamp":1451088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12012-015-9356-5","type":"journal-article","created":{"date-parts":[[2015,12,26]],"date-time":"2015-12-26T05:23:23Z","timestamp":1451107403000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-\u03baB, Hypertrophic Gene Expression and Oxidative Stress"],"prefix":"10.1007","volume":"17","author":[{"given":"Faisal","family":"Imam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif O.","family":"Al-Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Al-Harbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham M.","family":"Korashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq Ahmad","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Sayed-Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud N.","family":"Nagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Khalid Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Bahashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,26]]},"reference":[{"key":"9356_CR1","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., et al. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383\u20136391.","journal-title":"Cancer Research"},{"key":"9356_CR2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1471-2407-12-415","volume":"12","author":"R Hajek","year":"2012","unstructured":"Hajek, R., Bryce, R., Ro, S., Klencke, B., & Ludwig, H. (2012). Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R\/R MM). BMC Cancer, 12, 415\u2013521.","journal-title":"BMC Cancer"},{"issue":"17","key":"9356_CR3","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon, T. M., Deisseroth, A., Kaminskas, E., Kane, R. C., Koti, K. M., Rothmann, M. D., et al. (2013). Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma. Clinical Cancer Research, 19(17), 4559\u20134563.","journal-title":"Clinical Cancer Research"},{"key":"9356_CR4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/187152909787581372","volume":"9","author":"O Fuchs","year":"2009","unstructured":"Fuchs, O., Provaznikova, D., Marinov, I., Kuzelova, K., & Spicka, I. (2009). Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovascular & Hematological Disorders: Drug Targets, 9, 62\u201377.","journal-title":"Cardiovascular & Hematological Disorders: Drug Targets"},{"key":"9356_CR5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/ehm.12.26","volume":"5","author":"RZ Khan","year":"2012","unstructured":"Khan, R. Z., & Badros, A. (2012). Role of carfilzomib in the treatment of multiple myeloma. Expert Review of Hematology, 5, 361\u2013372.","journal-title":"Expert Review of Hematology"},{"key":"9356_CR6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","volume":"158","author":"R Vij","year":"2012","unstructured":"Vij, R., Siegel, D. S., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K., et al. (2012). An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology, 158, 739\u2013748.","journal-title":"British Journal of Haematology"},{"key":"9356_CR7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","volume":"14","author":"A Chari","year":"2014","unstructured":"Chari, A., & Hajje, D. (2014). Case series discussion of cardiac and vascular events following carfilzomib treatment: Possible mechanism, screening, and monitoring. BMC Cancer, 14, 915\u2013923.","journal-title":"BMC Cancer"},{"key":"9356_CR8","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., et al. (2013). Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 98, 1753\u20131761.","journal-title":"Haematologica"},{"issue":"14","key":"9356_CR9","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., et al. (2012). A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 120(14), 2817\u20132825.","journal-title":"Blood"},{"key":"9356_CR10","doi-asserted-by":"crossref","unstructured":"Force, W. I. T. (1980). Report of the WHO\/ISFC task force on the definition and classification of cardiomyopathies. British Heart Journal 44(6), 672\u2013673.","DOI":"10.1136\/hrt.44.6.672"},{"issue":"2","key":"9356_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0033-0620(84)90020-3","volume":"27","author":"WH Abelmann","year":"1984","unstructured":"Abelmann, W. H. (1984). Classification and natural history of primary myocardial disease. Progress in Cardiovascular Diseases, 27(2), 73\u201394.","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"5","key":"9356_CR12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O\u2019Connell, J., et al. (1996). Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation, 93(5), 841\u2013842.","journal-title":"Circulation"},{"issue":"2","key":"9356_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3923\/ijp.2008.78.87","volume":"4","author":"TS Shanmugarajan","year":"2008","unstructured":"Shanmugarajan, T. S., Arunsunder, M., Somasundaram, I., Krishnakumar, E., Sivaraman, D., & Ravichandiran, V. (2008). Protective effect of Ficus hispida Linn. on cyclophosphamide provoked oxidative myocardial injury in rat model. International Journal of Pharmacology, 4(2), 78\u201387.","journal-title":"International Journal of Pharmacology"},{"issue":"15","key":"9356_CR14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/eurheartj\/ehi342","volume":"26","author":"A Repetto","year":"2005","unstructured":"Repetto, A., Dal Bello, B., Pasotti, M., Agozzino, M., Vigano, M., Klersy, C., et al. (2005). Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: An innocent bystander? European Heart Journal, 26(15), 1519\u20131527.","journal-title":"European Heart Journal"},{"issue":"10","key":"9356_CR15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.biocel.2008.02.020","volume":"40","author":"SP Barry","year":"2008","unstructured":"Barry, S. P., Davidson, S. M., & Townsend, P. A. (2008). Molecular regulation of cardiac hypertrophy. International Journal of Biochemistry & Cell Biology, 40(10), 2023\u20132039.","journal-title":"International Journal of Biochemistry & Cell Biology"},{"issue":"4","key":"9356_CR16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.RES.86.4.386","volume":"86","author":"S Miyata","year":"2000","unstructured":"Miyata, S., Minobe, W., Bristow, M. R., & Leinwand, L. A. (2000). Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circulation Research, 86(4), 386\u2013390.","journal-title":"Circulation Research"},{"issue":"4","key":"9356_CR17","doi-asserted-by":"crossref","first-page":"H1814","DOI":"10.1152\/ajpheart.2001.280.4.H1814","volume":"280","author":"PJ Reiser","year":"2001","unstructured":"Reiser, P. J., Portman, M. A., Ning, X. H., & Schomisch Moravec, C. (2001). Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. American Journal of Physiology Heart and Circulatory Physiology, 280(4), H1814\u2013H1820.","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"key":"9356_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4143\/crt.2008.40.3.121","volume":"40","author":"H Lee","year":"2008","unstructured":"Lee, H., Son, C. B., Shin, S. H., & Kim, Y. S. (2008). Clinical correction between brain natriuretic peptide and anthracycline-induced cardiotoxicity. Cancer Research and Treatment, 40, 121\u2013126.","journal-title":"Cancer Research and Treatment"},{"issue":"19","key":"9356_CR19","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0195-668X(03)00476-7","volume":"24","author":"MR Cowie","year":"2003","unstructured":"Cowie, M. R., Jourdain, P., Maisel, A., Dahlstrom, U., Follath, F., Isnard, R., et al. (2003). Clinical applications of B-type natriuretic peptide (BNP) testing. European Heart Journal, 24(19), 1710\u20131718.","journal-title":"European Heart Journal"},{"issue":"4","key":"9356_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus, A., & Ghosh, S. (2009). The NF-\u03baB family of transcription factors and its regulation. Cold Spring Harbor Perspectives in Biology, 1(4), 1\u201314.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"4","key":"9356_CR21","doi-asserted-by":"crossref","first-page":"L622","DOI":"10.1152\/ajplung.00477.2005","volume":"290","author":"SF Liu","year":"2006","unstructured":"Liu, S. F., & Malik, A. B. (2006). NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology, 290(4), L622\u2013L645.","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"9356_CR22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cardiores.2004.08.007","volume":"65","author":"RP Brandes","year":"2005","unstructured":"Brandes, R. P., & Kreuzer, J. (2005). Vascular NADPH oxidases: Molecular mechanisms of activation. Cardiovascular Research, 65, 16\u201327.","journal-title":"Cardiovascular Research"},{"key":"9356_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-8981(98)00117-X","volume":"277","author":"D Konukoglu","year":"1998","unstructured":"Konukoglu, D., Serin, O., Kemerli, D. G., Serin, E., Hayirhoglu, A., & Oner, B. (1998). A study on the carotid artery intima-media thickness and its association with lipid peroxidation. Clinica Chimica Acta, 277, 91\u201398.","journal-title":"Clinica Chimica Acta"},{"key":"9356_CR24","first-page":"443","volume-title":"The liver: Biology and pathobiology","author":"M Inoue","year":"2011","unstructured":"Inoue, M. (2011). Protective mechanisms against reactive oxygen species. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jokoby, D. A. Schachter, & D. A. Shafritz (Eds.), The liver: Biology and pathobiology (5th ed., pp. 443\u2013459). New York: Raven Press.","edition":"5"},{"key":"9356_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jn\/134.3.489","volume":"134","author":"G Wu","year":"2004","unstructured":"Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., & Turner, N. D. (2004). Glutathione metabolism and its implications for health. Journal of Nutrition, 134, 489\u2013492.","journal-title":"Journal of Nutrition"},{"key":"9356_CR26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.1840130627","volume":"13","author":"CS Zindenberg","year":"1991","unstructured":"Zindenberg, C. S., Olin, K. L., & Villarweva, J. (1991). Ethanol induced changes in hepatic free radical defense mechanisms and fatty acid composition in the miniature pig. Hepatology, 13, 1185\u20131192.","journal-title":"Hepatology"},{"issue":"2","key":"9356_CR27","first-page":"80","volume":"3","author":"B Altinterim","year":"2014","unstructured":"Altinterim, B. (2014). Citrus, rutin and on their vein permeability effects. RJAEM, 3(2), 80\u201381.","journal-title":"RJAEM"},{"key":"9356_CR28","first-page":"1182","volume":"91","author":"S Heather","year":"1995","unstructured":"Heather, S., Demrow, B. S., Peter, R., Slane, B. S., & John, D. F. (1995). Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. American Heart Association, 91, 1182\u20131188.","journal-title":"American Heart Association"},{"issue":"15","key":"9356_CR29","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1021\/jf8006568","volume":"56","author":"O Benavente-Garcia","year":"2008","unstructured":"Benavente-Garcia, O., & Castillo, J. (2008). Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and antiinflammatory activity. Journal of Agriculture and Food Chemistry, 56(15), 6185\u20136205.","journal-title":"Journal of Agriculture and Food Chemistry"},{"key":"9356_CR30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3945\/jn.111.137877","volume":"141","author":"SK Panchal","year":"2011","unstructured":"Panchal, S. K., Poudyal, H., Arumugam, T. V., & Brown, L. (2011). Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. Journal of Nutrition, 141, 1062\u20131069.","journal-title":"Journal of Nutrition"},{"issue":"6","key":"9356_CR31","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3945\/jn.111.157263","volume":"142","author":"SK Panchal","year":"2012","unstructured":"Panchal, S. K., Poudyal, H., & Brown, L. (2012). Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in DIET-induced metabolic syndrome in rats. Journal of Nutrition, 142(6), 1026\u20131032.","journal-title":"Journal of Nutrition"},{"key":"9356_CR32","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang, J., Wang, Z., Fang, Y., Jiang, J., Zhao, F., Wong, H., et al. (2011). Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metabolism and Disposition, 39, 1873\u20131882.","journal-title":"Drug Metabolism and Disposition"},{"key":"9356_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.09.001","volume":"102","author":"F Imam","year":"2015","unstructured":"Imam, F., Al-Harbi, N. O., Al-Harbi, M. M., Ansari, M. A., Zoheir, K. M., Iqbal, M., et al. (2015). Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-\u03baB activation against LPS-induced acute lung injury in mice. Pharmacological Research, 102, 1\u201311.","journal-title":"Pharmacological Research"},{"key":"9356_CR34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265\u2013275.","journal-title":"Journal of Biological Chemistry"},{"issue":"1\u20133","key":"9356_CR35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tox.2004.04.011","volume":"201","author":"HM Korashy","year":"2004","unstructured":"Korashy, H. M., & El-Kadi, A. O. (2004). Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology, 201(1\u20133), 153\u2013172.","journal-title":"Toxicology"},{"key":"9356_CR36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351\u2013358.","journal-title":"Analytical Biochemistry"},{"key":"9356_CR37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","volume":"25","author":"J Sedlak","year":"1968","unstructured":"Sedlak, J., & Lindsay, R. H. (1968). Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman\u2019s reagent. Analytical Biochemistry, 25, 192\u2013205.","journal-title":"Analytical Biochemistry"},{"issue":"9","key":"9356_CR38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/15376516.2014.963773","volume":"24","author":"NO Al-Harbi","year":"2014","unstructured":"Al-Harbi, N. O., Imam, F., Nadeem, A., Al-Harbi, M. M., Iqbal, M., Rahman, S., et al. (2014). Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren. Toxicology Mechanisms and Methods, 24(9), 697\u2013702.","journal-title":"Toxicology Mechanisms and Methods"},{"key":"9356_CR39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 339, 900\u2013905.","journal-title":"New England Journal of Medicine"},{"key":"9356_CR40","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","volume":"109","author":"ETH Yeh","year":"2004","unstructured":"Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., et al. (2004). Review: Current perspective: Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation, 109, 3122\u20133131.","journal-title":"Circulation"},{"key":"9356_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/619185","volume":"2012","author":"O Al-Shabanah","year":"2012","unstructured":"Al-Shabanah, O., Aleisa, A. M., Hafez, M. M., Al-Rejaie, S. S., Al-Yahya, A. A., Bakheet, S. A., et al. (2012). Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-\u03b2\/Smad p53 pathway in rat model. Oxidative Medicine and Cellular Longevity, 2012, 1\u20137.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"3","key":"9356_CR42","first-page":"275","volume":"26","author":"B Piura","year":"2005","unstructured":"Piura, B., & Rabinovich, A. (2005). Doxorubicin and ifosfamidemesna in advanced and recurrent uterine sarcomasl. European Journal of Gynaecological Oncology, 26(3), 275\u2013278.","journal-title":"European Journal of Gynaecological Oncology"},{"key":"9356_CR43","first-page":"419","volume":"45","author":"O Al-Shabanah","year":"1998","unstructured":"Al-Shabanah, O., Mansour, M., El-Kashef, H., & Al-Bekairi, A. (1998). Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochemistry and Molecular Biology International, 45, 419\u2013427.","journal-title":"Biochemistry and Molecular Biology International"},{"key":"9356_CR44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/10715760100301581","volume":"35","author":"MA el-Missiry","year":"2001","unstructured":"el-Missiry, M. A., Othman, A. I., Amer, M. A., & Abdel-Aziz, M. A. (2001). Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. Free Radical Research, 35, 575\u2013581.","journal-title":"Free Radical Research"},{"key":"9356_CR45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0960327110369819","volume":"30","author":"A Rashikh","year":"2011","unstructured":"Rashikh, A., Najmi, A. K., Akhtar, M., Mahmood, D., Pillai, K. K., & Ahmad, S. J. (2011). Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Human and Experimental Toxicology, 30, 102\u2013109.","journal-title":"Human and Experimental Toxicology"},{"key":"9356_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1043-6618(03)00185-3","volume":"48","author":"M Yagmurca","year":"2003","unstructured":"Yagmurca, M., Fadillioglu, E., Erdogan, H., Ucar, M., Sogut, S., & Irmak, M. K. (2003). Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacological Research, 48, 377\u2013382.","journal-title":"Pharmacological Research"},{"issue":"1","key":"9356_CR47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12012-014-9266-y","volume":"15","author":"HM Korashy","year":"2015","unstructured":"Korashy, H. M., Al-Suwayeh, H. A., Maayah, Z. H., Ansari, M. A., Ahmad, S. F., & Bakheet, S. A. (2015). Mitogen-activated protein kinases pathways mediate the sunitinib-induced hypertrophy in rat cardiomyocyte H9c2 cells. Cardiovascular Toxicology, 15(1), 41\u201351.","journal-title":"Cardiovascular Toxicology"},{"issue":"3","key":"9356_CR48","first-page":"725","volume":"88","author":"ZH Maayah","year":"2014","unstructured":"Maayah, Z. H., Ansari, M. A., El Gendy, M. A., Al-Arifi, M. N., & Korashy, H. M. (2014). Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Archives of Toxicology, 88(3), 725\u2013738.","journal-title":"Archives of Toxicology"},{"issue":"3","key":"9356_CR49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cvr\/cvq068","volume":"87","author":"B Das","year":"2010","unstructured":"Das, B., Young, D., Vasanji, A., Gupta, S., Sarkar, S., & Sen, S. (2010). Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovascular Research, 87(3), 524\u2013534.","journal-title":"Cardiovascular Research"},{"key":"9356_CR50","first-page":"57","volume":"7","author":"S Surget","year":"2013","unstructured":"Surget, S., Khoury, M. P., & Bourdon, J. C. (2013). Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. OncoTargets and Therapy, 7, 57\u201368.","journal-title":"OncoTargets and Therapy"},{"issue":"4","key":"9356_CR51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1054\/drup.1999.0094","volume":"2","author":"JC Cusack","year":"1999","unstructured":"Cusack, J. C., Liu, R., & Baldwin, A. S. (1999). NF-kappa B and chemoresistance: Potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resistance Updates, 2(4), 271\u2013273.","journal-title":"Drug Resistance Updates"},{"issue":"5","key":"9356_CR52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1535-6108(02)00068-5","volume":"1","author":"V Tergaonkar","year":"2002","unstructured":"Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., & Verma, I. (2002). p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell, 1(5), 493\u2013503.","journal-title":"Cancer Cell"},{"issue":"5","key":"9356_CR53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.cdd.4401838","volume":"13","author":"ND Perkins","year":"2006","unstructured":"Perkins, N. D., & Gilmore, T. D. (2006). Good cop, bad cop: the different faces of NF-kappaB. Cell Death and Differentiation, 13(5), 759\u2013772.","journal-title":"Cell Death and Differentiation"},{"issue":"2","key":"9356_CR54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s10753-014-9994-y","volume":"38","author":"SF Ahmad","year":"2015","unstructured":"Ahmad, S. F., Attia, S. M., Bakheet, S. A., Zoheir, K. M. A., Ansari, M. A., Korashy, H. M., et al. (2015). Naringin attenuates the development of carrageenan-induced acute lung inflammation through inhibition of NF-\u03bab, STAT3 and pro-inflammatory mediators and enhancement of I\u03baB\u03b1 and anti-inflammatory cytokines. Inflammation, 38(2), 846\u2013857.","journal-title":"Inflammation"},{"key":"9356_CR55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","volume":"60","author":"MA Ibrahim","year":"2009","unstructured":"Ibrahim, M. A., Ashour, O. M., Ibrahim, Y. F., El-Bitar, H. I., Gomaa, W., & Abdel-Rahim, S. R. (2009). Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacological Research, 60, 373\u2013381.","journal-title":"Pharmacological Research"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-015-9356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-015-9356-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-015-9356-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-015-9356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T19:52:29Z","timestamp":1653940349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-015-9356-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,26]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["9356"],"URL":"https:\/\/doi.org\/10.1007\/s12012-015-9356-5","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,26]]}}}